Brilliant summary slide re:RA and PsA during an as-always entertaiing by Dr. Seo Personal opinion? -Persolimab will have narrow role & may cause CA -BIME will be 2nd line for PsA -Tyk-2's will be the next big thing Also... time for H2H trials!!! @RheumNow #ACR23 https://t.co/lDvsK8h7WH

#ACR23 YiR! Dr. P. Seo reviews 2023 novel therapeutic agents we may see on the horizon. @RheumNow https://t.co/d0V41jAh3G

Considering a career in Rheumatology? Dr. Philip Seo shares latest data from Lancet Rheumatology on the burden of disease of MSK disorders 👉123%⬆️since 1990 👉⬆️by 50% in 2050! Year in Review #ACR23 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr https://t.co/iypUn9MTu6

Can colchine reduce need for knee/hip replacement? Dr Seo #YearReview #ACR23 @RheumNow https://t.co/EpMl2nDZQ6

• https://twitter.com/KDAO2011/status/1723728623650410910/photo/1

NORD-STAR study RA pts treated with MTX + certolizumab, abatacept, tocilizumab or triple therapy Certolizumab and Abatacept share 1st place! Toci 2nd Should we place abatacept higher on the RA tx hierarchy? @RheumNow #ACR23 https://t.co/QvyzkLOcmX

Still disgesting NORD-STAR, kind of surprised by the TCZ response? As per usual, ABA is probably an under-used option for RA @RheumNow #ACR23 https://t.co/QKyeuhqnXB

Novel therapeutics for #inflammatoryArthritis #YearInReciew #ACR23 @RheumNow https://t.co/9flVkGRn8v

• https://twitter.com/KDAO2011/status/1723729765440573907/photo/1

Novel therapeutics for #SLE and #SSc #ACR23 @RheumNow https://t.co/yBSaTpNZLN

• https://twitter.com/KDAO2011/status/1723730203313348851/photo/1

#ACR23 I’ll be at the Poster Hall tomorrow 12/11/23 between 9-11 am to present our work on clinical and biomarkers to exclude imminent autoimmune connective tissue disease #lupus #sjogren in people with ANA+. Do come and say hi 👋🏼 😃 https://t.co/wzRB7QXZsF

Takeaways from #ACR23 #ReviewCourse session on Systemic Sclerosis Screening for Organ Involvement - Dr. Francesco Boin 1. Always approach SSc as a systemic disease (see slide). Survival is determined by subset (limited vs diffuse) and organ manifestations. 2. Autoantibodies… https://t.co/TmrPqLJYzD https://t.co/ajHDVpUbhO

Axial PsA or AS? #ACR23 Abs #0492 finds age > 45 at LBP onset, female sex, higher frequency of PsO, and shorter time to dx may be better predictors of axial PsA. https://t.co/3sEj8NxtzP @rheumnow https://t.co/nV7NHk7WtD

Deucravacitinib tx found to have comparable effects on PsA disease activity and PROs after 16 weeks in both male and female patients. #ACR23 Abs 0485 https://t.co/w36rX3B77K @rheumnow https://t.co/q41ioJDMML

Racial/ethnic minority PsA pts less likely to be diagnosed w/in 12 mos from symptom onset (50% vs 71%; P < 0.001) and more frequently uninsured (8% vs. 1%; P < 0.001) compared to white pts. #ACR23 Abs #0490 https://t.co/MKO9hblGYT @rheumnow https://t.co/K8GgkhHOqw

In bDMARD-IR AS patients, UPA led to numerically greater improvements vs PBO in physical activity as measured by a wearable device over 14 wks, especially in sedentary patients. #ACR23 Abs #0530 https://t.co/6Me2XctK6D @rheumnow https://t.co/c6E2GfAGt4

Large Chicago study Abs #0535 at #ACR23 biologic tx prescribed more often for males, Non-Hispanic Blacks and Latinx in AS. Low SES, measured by SDI, and insurance status did not affect if pt received bDMARD. https://t.co/MdDuNPMCC9 @rheumnow https://t.co/Oa9aC3rbb0